4//SEC Filing
Davis Blaine 4
Accession 0001453687-25-000025
CIK 0001453687other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 4:20 PM ET
Size
9.1 KB
Accession
0001453687-25-000025
Insider Transaction Report
Form 4
Davis Blaine
Chief Financial Officer
Transactions
- Award
Employee Stock Option (right to buy)
2025-01-02+64,600→ 64,600 totalExercise: $16.93Exp: 2035-01-01→ Common Stock (64,600 underlying) - Award
Common Stock
2025-01-02+22,000→ 102,800 total
Holdings
- 103,666
Employee Stock Option (right to buy)
Exercise: $19.66Exp: 2034-01-01→ Common Stock (103,666 underlying)
Footnotes (4)
- [F1]Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.
- [F2]On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- [F3]This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.
- [F4]This option vested as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter.
Documents
Issuer
Cartesian Therapeutics, Inc.
CIK 0001453687
Entity typeother
Related Parties
1- filerCIK 0001802188
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 4:20 PM ET
- Size
- 9.1 KB